FDA Warns Of Clip Lock Risk With Abbott's MitraClip
Executive Summary
The US FDA is alerting providers about a potential clip lock malfunction with Abbott’s MitraClip, a device used to treat a disorder involving the heart’s mitral valve.
You may also be interested in...
Researchers Suggest More Care In Using Abbott’s MitraClip
New data aggregated from over 5,000 reported adverse events suggests that patients should be aware of risks using MitraClip for TEER and operators should take more caution in handling the device.
CMS Extends National Medicare Coverage For Transcatheter Mitral Valve Repair
Medicare now covers transcatheter edge-to-edge repair for both functional and degenerative mitral regurgitation under specific conditions.
Functional MR Added To FDA-Approved Indication For Abbott's MitraClip
The new indication covers functional mitral regurgitation, also known as secondary mitral regurgitation, which represents two-to-three times as many patients as the primary mitral regurgitation population MitraClip is already labeled for. The approval is supported by results from the COAPT trial, the first randomized trial to show that a mitral-valve repair could improve outcomes in patients with secondary mitral regurgitation.